2 FTSE 350 growth stocks I’d buy ASAP

Now could be the perfect time to pick up shares in these two FTSE 350 (INDEXFTSE:NMX) growth companies.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Hikma Pharmaceuticals (LSE: HIK) heads the FTSE 100 fallers board today, following the release of a trading update. Its shares dived as much as 7.5% early doors but have since regained a bit of ground to trade down 4.7% at 1,620p.

In a broader context, the shares were above 2,100p as recently as March and are almost 40% below their 52-week high of 2,676p last summer. Despite the decline and today’s badly-received trading update, I believe now could be the perfect time to buy a slice of the business.

Revenue downgrade

Hikma today reiterated previous full-year revenue guidance for its Injectibles division (“$800m to $825m”) and Branded division (“grow in the low-single digits”, so around $570m). However, it said it now expects revenue from its Generics business to be “around $670m”, compared with previous guidance of “around $800m”.

A revenue downgrade had actually been signposted last week when the company announced that there was now a “low likelihood” of its generic version of GlaxoSmithKline‘s Advair Diskus asthma treatment receiving approval from the US Food and Drug Administration in the current year. The previous revenue guidance of $800m for the Generics division included 15% from new product launches, “primarily generic Advair, which is assumed to be launched in the second half of the year”. So today’s lower guidance of $670m largely reflects the delay to approval, although also some pricing pressure in the US generics market.

Compelling growth story

In my view, you could take generic Advair completely out of the picture and Hikma would still represent a compelling growth story. It currently sells well over 700 products worldwide and has a strong position in the Middle East and North Africa, accounting for about a third of group revenue.

Even without generic Advair, I estimate Hikma trades on a mid-teens price-to-earnings (P/E) ratio for 2018. This seems too generous for a company with excellent medium- and long-term growth prospects. As such, I rate the shares a ‘buy’ at their current level and anticipate them advancing when the market starts looking forward to next year. The advance could be rapid should there be any positive news on generic Advair.

Under-appreciated

Another company whose growth prospects I believe are currently under-appreciated by the market is FTSE 250 infrastructure group Balfour Beatty (LSE: BBY). The company got into all sorts of trouble a few years ago, much of it stemming from an aggressive acquisition strategy over the previous decade. Its shares hit a multi-year low of 152p in October 2015.

However, following sweeping boardroom changes, it has made excellent progress and returned to profit in 2016. It’s now focused on its core markets in the UK and US, where governments are committed to large-scale expenditure on infrastructure.

Set to re-rate

Having done the heavy lifting of simplifying the group, the new management expects to achieve industry-standard profit margins over the next two years and industry-leading performance in the medium term.

The shares have recovered from their 2014 low to 280p but the market is still undervaluing the prospective growth, in my view. A current-year forecast P/E of 22, falls rapidly to 13.6 next year on consensus analyst expectations of a 50% increase in earnings. The shares look very buyable to me on the basis of a re-rating, as market confidence in the company grows.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Should I follow Warren Buffett and sell my favourite shares?

Billionaire US investor Warren Buffett has been selling tons of Apple shares and other stocks of businesses he thinks are…

Read more »

Investing Articles

As like-for-like sales continue to fall, is the B&M European Value Retail SA (LSE:BME) share price a bargain?

B&M European Value Retail is known for its low prices, but could growing like-for-like sales make the share price the…

Read more »

Illustration of flames over a black background
Investing Articles

After rocketing 232% in a year can this red-hot FTSE 250 stock keep going gangbusters?

Harvey Jones says this FTSE 250 stock's on fire after smashing the index over the last year. It's cheaper than…

Read more »

Investing Articles

The Burberry share price has jumped 15% this morning! Time to pile in?

Harvey Jones was thrilled to wake up this morning and find the Burberry share price flying, but he's still sitting…

Read more »